FOX News correspondent Jonathan Serrie joins Special Report with that latest
Several top health experts are touting new federal guidelines on practices considered safe for fully vaccinated populations against COVID-19, while underscoring the importance of masking up in high risk and public settings.
The highly anticipated guidance from the Centers for Disease Control and Prevention (CDC) issued this week greenlighted unmasked indoor gatherings among fully vaccinated individuals, and also suggested fully vaccinated people mingling indoors with unvaccinated people at low-risk for severe COVID-19 poses low risk, among other recommendations. However, the CDC advised everyone should avoid larger indoor gatherings and mask up in public and high-risk settings regardless of vaccination status.
Vaccine demand | is there enough covid-19 vaccine? 11alive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 11alive.com Daily Mail and Mail on Sunday newspapers.
Below is Alston & Bird’s
Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.
Week in Review Highlight of the Week:
This week, CMS announced additional funding to support the 2021 Special Enrollment Period (SEP) for Marketplace health coverage. Read more about the announcement and other news below.
I. Regulations, Notices & Guidance
On March 4, 2021, the Food and Drug Agency (FDA) issued guidance entitled,
COVID-19 Container Closure System and Component Changes. FDA is issuing this guidance to collate recommendations for appropriate reporting category and the content of post-approval change submissions across numerous FDA guidance documents. This guidance conveys recommendations to holders of approved new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new
340B: 266 House Legislators Want Fines for Drug Companies
Two hundred sixty-six members of the House of Representatives have told the Department of Health and Human Services that HHS should fine drug companies that deny 340B discounts to hospitals for drugs dispensed by contract pharmacies and to make drug companies pay hospitals back for discounts that were withheld. The letter says it’s the long-held position of the Health Resources and Services Administration that drug companies must provide 340B discounts to hospitals and clinics that qualify, regardless of whether hospitals dispense the drugs themselves. The letter states there are no provisions in the statute that allow manufacturers to set conditions or impede access to 340B discounts.
Oculoplastic Surgery Market To Power And Cross USD 11 05 Bn By 2028 - Media Releases reseller.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reseller.co.nz Daily Mail and Mail on Sunday newspapers.